|Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes|
|Shi, YF; Pan, CY; Hill, J; Gao, Y|
|关键词||Cardiovascular Risk Factors Chinese Newly Diagnosed Type 2 Diabetes Obesity Orlistat|
|WOS标题词||Science & Technology|
|类目[WOS]||Endocrinology & Metabolism|
|研究领域[WOS]||Endocrinology & Metabolism|
|关键词[WOS]||MODEST WEIGHT-LOSS ; RANDOMIZED CONTROLLED-TRIAL ; CARDIOVASCULAR RISK-FACTORS ; LONG-TERM ; CLINICAL-EFFICACY ; BODY-WEIGHT ; DISEASE ; MELLITUS ; METFORMIN ; HEALTH|
Aims Orlistat promotes weight loss in overweight and obese patients with Type 2 diabetes receiving hypoglycaemic treatment, but has not been investigated in patients with newly diagnosed and previously untreated Type 2 diabetes. We evaluated the efficacy of 24 weeks′ treatment with orlistat, combined with a mildly reduced-calorie diet, on weight loss and glycaemic control in overweight and obese patients with newly diagnosed and previously untreated Type 2 diabetes.
Methods A total of 249 Chinese patients (body mass index 25-40 kg/m(2)) with recently diagnosed Type 2 diabetes were randomized to placebo (n = 124) or orlistat 120 mg (n = 125) three times daily; all patients followed a mildly reduced-calorie diet. Patients had HbA(1c) 6.5-8.5% (mean 7.3%) and had never received any glucose-lowering medication.
Results Orlistat-treated patients achieved significantly greater weight loss at the study end than placebo-treated patients (-5.4 vs. -2.4 kg; P < 0.0001). More orlistat than placebo patients lost >= 5% (60.5 vs. 26.8%; P < 0.0001) and >= 10% of their body weight (20.2 vs. 4.9%; P = 0.0002). A significantly greater decrease in HbA(1c) from baseline was obtained with orlistat than placebo (-1.0 vs. -0.6%; P = 0.0008). Orlistat-treated patients achieved a significantly greater decrease in fasting plasma glucose (-1.3 vs. -0.5 mmol/l; P = 0.0003) and in the 2-h oral glucose tolerance test (-4.1 vs. -1.4 mmol/l; P < 0.0001) than placebo recipients. Also, more orlistat- than placebo-treated patients improved from diabetic status to normal or impaired glucose tolerance (44.3 vs. 32.5%; P = 0.0763) after 24 weeks. Orlistat also produced improvements in lipid profiles and waist circumference.
Conclusions In combination with a mildly reduced-calorie diet, orlistat significantly reduces body weight, and improves glycaemic control and several cardiovascular risk factors in overweight and obese Chinese patients with newly diagnosed Type 2 diabetes.
|作者单位||1.Roche Prod Pty Ltd, Dee Why, NSW, Australia|
2.Beijing 301 Hosp, Dept Endocrinol, Beijing, Peoples R China
3.Beijing Union Med Coll Hosp, Dept Endocrinol, Beijing 100730, Peoples R China
4.Peking Univ, Hosp 1, Dept Endocrinol, Beijing 100871, Peoples R China
|Shi, YF,Pan, CY,Hill, J,et al. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes[J]. DIABETIC MEDICINE,2005,22(12):1737-1743.|
|APA||Shi, YF,Pan, CY,Hill, J,&Gao, Y.(2005).Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes.DIABETIC MEDICINE,22(12),1737-1743.|
|MLA||Shi, YF,et al."Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes".DIABETIC MEDICINE 22.12(2005):1737-1743.|